Cancer nanomedicine

Sangeeta N Bhatia^{1

2

3

4

5}, Xiaoyuan Chen^{6

7

8

9

10

11}, Marina A Dobrovolskaia¹², Twan Lammers¹³

Affiliations

¹ Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA. sbhatia@mit.edu.
² Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA. sbhatia@mit.edu.
³ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. sbhatia@mit.edu.
⁴ Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. sbhatia@mit.edu.
⁵ Howard Hughes Medical Institute, Chevy Chase, MD, USA. sbhatia@mit.edu.
⁶ Department of Diagnostic Radiology, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
⁷ Department of Surgery, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
⁸ Department of Chemical and Biomolecular Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
⁹ Department of Biomedical Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
¹⁰ Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
¹¹ Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
¹² Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. marina@mail.nih.gov.
¹³ Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging (ExMI), Center for Biohybrid Medical Systems (CBMS), RWTH Aachen University Clinic, Aachen, Germany. tlammers@ukaachen.de.

PMID: 35941223
PMCID: PMC9358926
DOI: 10.1038/s41568-022-00496-9

Cancer nanomedicine

Sangeeta N Bhatia et al. Nat Rev Cancer. 2022 Oct.

. 2022 Oct;22(10):550-556.

doi: 10.1038/s41568-022-00496-9. Epub 2022 Aug 8.

Authors

Sangeeta N Bhatia^{1

2

3

4

5}, Xiaoyuan Chen^{6

7

8

9

10

11}, Marina A Dobrovolskaia¹², Twan Lammers¹³

Affiliations

¹ Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA. sbhatia@mit.edu.
² Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA. sbhatia@mit.edu.
³ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. sbhatia@mit.edu.
⁴ Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. sbhatia@mit.edu.
⁵ Howard Hughes Medical Institute, Chevy Chase, MD, USA. sbhatia@mit.edu.
⁶ Department of Diagnostic Radiology, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
⁷ Department of Surgery, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
⁸ Department of Chemical and Biomolecular Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
⁹ Department of Biomedical Engineering, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
¹⁰ Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
¹¹ Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. chen.shawn@nus.edu.sg.
¹² Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. marina@mail.nih.gov.
¹³ Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging (ExMI), Center for Biohybrid Medical Systems (CBMS), RWTH Aachen University Clinic, Aachen, Germany. tlammers@ukaachen.de.

PMID: 35941223
PMCID: PMC9358926
DOI: 10.1038/s41568-022-00496-9

Abstract

The field of cancer nanomedicine seeks to overcome the inherent shortcomings of conventional cancer diagnostics and therapies. Yet despite the surge of interest in and attractive attributes of nanotechnologies, challenges remain in their clinical translation, prompting some to argue that they have not yet reached their true potential. In this Viewpoint article, we asked four experts for their opinions on how we can fulfil the great promise of nanomedicine for the detection, diagnosis and treatment of patients with cancer.

PubMed Disclaimer

Conflict of interest statement

S.N.B. reports compensation for cofounding, consulting, and/or board membership in Glympse Bio, Satellite Bio, CEND Therapeutics, Xilio Therapeutics, Catalio Capital, Intergalactic Therapeutics, Port Therapeutics, Vertex Pharmaceuticals, Danaher and Moderna, and receives sponsored research funding from Johnson & Johnson, Revitope and Owlstone Medical. X.C. is a co-founder of Shanghai Lannacheng Biotech Co., Ltd (China), Editor-in-Chief of Theranostics (Ivyspring, Australia), President of Theranostics Consulting LLC (USA) and a consultant for Molecular Targeting Technologies, Inc. (USA) and Yantai Dongcheng Pharmaceutical Group (China). M.A.D. and T.L. declare no competing interests.

References

1. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng. Transl. Med. 2019;4:e10143. - PMC - PubMed
1. Market Watch. Liposomal doxorubicin market size 2022 global trends, COVID-19 impact analysis, industry growth, types, applications, future scope, prominent players, shares, research with regions, forecast to 2028. MarketWatchhttps://www.marketwatch.com/press-release/vyxeos-market-2022-demand-shar... (2022).
1. News Channel Southeast Nebraska. Liposomes drug delivery market size in 2022 is estimated to grow at a modest CAGR of more than 12.8% during the forecast period 2022–2026 with top countries data | In-depth 140 pages report. News Channel Nebraskahttps://southeast.newschannelnebraska.com/story/45768056/liposomes-drug-... (2022).
1. Ward, L. B. A Medical Wonder That Isn’t–Yet. New York Timeshttps://www.nytimes.com/1990/05/06/business/a-medical-wonder-that-isn-t-... (1990).
1. Wolff JA, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465–1468. doi: 10.1126/science.1690918. - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cancer nanomedicine

Affiliations

Cancer nanomedicine

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical